Citizens JMP upgraded Stryker from Mkt Perform to Mkt Outperform and set a new price target of $440.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2026 | $410.00 | Outperform | Leerink Partners |
| 2/20/2026 | Outperform | William Blair | |
| 1/27/2026 | $387.00 | Hold | TD Cowen |
| 1/6/2026 | $418.00 | Mkt Perform → Outperform | Raymond James |
| 12/19/2025 | $440.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 9/18/2025 | $420.00 | Neutral | Rothschild & Co Redburn |
| 2/26/2025 | $450.00 | Buy | Citigroup |
| 12/2/2024 | $370.00 → $445.00 | Equal-Weight → Overweight | Morgan Stanley |
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00
William Blair initiated coverage of Stryker with a rating of Outperform
TD Cowen resumed coverage of Stryker with a rating of Hold and set a new price target of $387.00
PORTAGE, Mich., June 24, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced a new partnership with Major Champion and globally recognized golfer Shane Lowry at the Travelers Championship in Cromwell, Connecticut, naming him a sponsored brand ambassador for its Joint Replacement division. Through this collaboration, Lowry will share a deeply personal story, highlighting the critical role caregivers play in supporting loved ones through joint pain, surgery and recovery. As a caregiver to his father, Brendan, a former Gaelic football p
Issued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1
PORTAGE, Mich., June 2, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures. "Revision procedures are some of the most demanding cases surgeons face, especially when metal cutting is involved," said Mike Carlin, president of Stryker's Ortho Tech division. "TPX HD was designed with tho
SD - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
10-Q - STRYKER CORP (0000310764) (Filer)
GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s
Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy
Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 m
Portage, Michigan, April 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2026: First Quarter Results Reported net sales increased 2.6% to $6.0 billionOrganic net sales increased 2.4%Reported operating income margin of 15.5%Adjusted operating income margin(1) contracted 180 bps to 21.1%Reported EPS increased 14.2% to $1.93 Adjusted EPS(1) decreased 8.5% to $2.60 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 5.0 % 1.4 % 3.6 % 2.7 % 0.9 %Orthopaedics